---
title: "Seelos Therapeutics, Inc. (SEELQ.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/SEELQ.US.md"
symbol: "SEELQ.US"
name: "Seelos Therapeutics, Inc."
industry: "Pharmaceuticals"
datetime: "2026-05-21T01:33:12.983Z"
locales:
  - [en](https://longbridge.com/en/quote/SEELQ.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/SEELQ.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/SEELQ.US.md)
---

# Seelos Therapeutics, Inc. (SEELQ.US)

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [eelostherapeutics.com](https://eelostherapeutics.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:13.000Z

**Overall: D (0.60)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 178 / 189 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 76.05% |  |
| Net Profit YoY | 105.04% |  |
| P/B Ratio | 0.00 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 136.29 |  |
| Revenue | 2014000.00 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -10.86% | D |
| Profit Margin | 203.13% | A |
| Gross Margin | -100.80% | E |
| Revenue YoY | 76.05% | A |
| Net Profit YoY | 105.04% | A |
| Total Assets YoY | -79.97% | E |
| Net Assets YoY | 40.37% | A |
| Cash Flow Margin | -324.47% | E |
| OCF YoY | 76.05% | A |
| Turnover | 0.28 | D |
| Gearing Ratio | 1281.56% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Seelos Therapeutics, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "76.05%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "105.04%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.00",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "136.29",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "2014000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-10.86%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "203.13%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "-100.80%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "76.05%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "105.04%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "-79.97%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "40.37%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-324.47%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "76.05%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.28",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "1281.56%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 0.00 | 1/189 | 0.00 | 0.00 | 0.00 |
| PB | 0.00 | 194/189 | - | - | - |
| PS (TTM) | 0.00 | 2/189 | 0.00 | 0.00 | 0.00 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/SEELQ.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/SEELQ.US/norm.md)
- [Related News](https://longbridge.com/en/quote/SEELQ.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/SEELQ.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**